These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 22166891

  • 1. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity.
    Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K.
    Drug Metab Pharmacokinet; 2012; 27(3):294-300. PubMed ID: 22166891
    [Abstract] [Full Text] [Related]

  • 2. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.
    Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K.
    Life Sci; 2011 Apr 11; 88(15-16):730-6. PubMed ID: 21356216
    [Abstract] [Full Text] [Related]

  • 3. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes.
    Yamaori S, Kushihara M, Yamamoto I, Watanabe K.
    Biochem Pharmacol; 2010 Jun 01; 79(11):1691-8. PubMed ID: 20117100
    [Abstract] [Full Text] [Related]

  • 4. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
    Yamaori S, Okamoto Y, Yamamoto I, Watanabe K.
    Drug Metab Dispos; 2011 Nov 01; 39(11):2049-56. PubMed ID: 21821735
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19.
    Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K.
    Drug Metab Pharmacokinet; 2013 Nov 01; 28(4):332-8. PubMed ID: 23318708
    [Abstract] [Full Text] [Related]

  • 10. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes.
    Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K.
    Life Sci; 2011 Aug 01; 89(5-6):165-70. PubMed ID: 21704641
    [Abstract] [Full Text] [Related]

  • 11. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
    Wen X, Wang JS, Backman JT, Kivistö KT, Neuvonen PJ.
    Drug Metab Dispos; 2001 Nov 01; 29(11):1359-61. PubMed ID: 11602509
    [Abstract] [Full Text] [Related]

  • 12. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT.
    Br J Clin Pharmacol; 2001 Nov 01; 52(5):547-53. PubMed ID: 11736863
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
    Anderson GD, Chan LN.
    Clin Pharmacokinet; 2016 Nov 01; 55(11):1353-1368. PubMed ID: 27106177
    [Abstract] [Full Text] [Related]

  • 14. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes.
    Nakashima A, Kawashita H, Masuda N, Saxer C, Niina M, Nagae Y, Iwasaki K.
    Xenobiotica; 2005 Jun 01; 35(6):589-602. PubMed ID: 16192110
    [Abstract] [Full Text] [Related]

  • 15. The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.
    Qian Y, Gurley BJ, Markowitz JS.
    J Clin Psychopharmacol; 2019 Jun 01; 39(5):462-471. PubMed ID: 31433338
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. In Vitro Inhibition of Carboxylesterase 1 by Major Cannabinoids and Selected Metabolites.
    Qian Y, Wang X, Markowitz JS.
    Drug Metab Dispos; 2019 May 01; 47(5):465-472. PubMed ID: 30833288
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes.
    Wang Z, Sun W, Huang CK, Wang L, Xia MM, Cui X, Hu GX, Wang ZS.
    Drug Dev Ind Pharm; 2015 Apr 01; 41(4):613-6. PubMed ID: 24517573
    [Abstract] [Full Text] [Related]

  • 19. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
    Bansal S, Paine MF, Unadkat JD.
    Drug Metab Dispos; 2022 Apr 01; 50(4):351-360. PubMed ID: 35115300
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Bansal S, Zamarripa CA, Spindle TR, Weerts EM, Thummel KE, Vandrey R, Paine MF, Unadkat JD.
    Clin Pharmacol Ther; 2023 Sep 01; 114(3):693-703. PubMed ID: 37313955
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.